Krina K. Patel, MD, MSc, is an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

“The biggest update is that the overall response rate is still 96%, and then [regarding] depth of response, the complete response [CR]/stringent CR rate is 74%. [We have] big minimal residual disease [MRD] data on the majority of our patients now. [In total], 95% of patients were MRD undetectable at [a sensitivity of] 10

Krina K. Patel, MD, MSc, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 iMMagine-1 trial (NCT05396885) investigating anitocabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.